Cell-Mediated Immunoassay Using Multi-Viral Peptide Pool
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing cell-mediated immune competence, such as Cylex Immunknow and Quantiferon Monitor, provide inconsistent results and are not suitable for determining immune responses to a wide range of individuals, limiting their effectiveness in clinical applications like transplantation, cancer, and vaccine trials.
Innovation Solution
A cell-mediated immunoassay using a pool of peptides derived from at least three viral antigens, specifically hexon protein of human adenovirus 3, matrix protein 1 of influenza virus, nucleocapsid protein of influenza virus, and fusion glycoprotein G0 of respiratory syncytial virus, to detect immune responses in peripheral blood mononuclear cells, allowing for a more comprehensive assessment of immune competence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a single viral antigen is used in the immunoassay, then the assay is simple to perform, but it cannot determine immune competence across a wide range of individuals with diverse immune responses
Solution Approach 1:
The patent combines multiple viral antigens (from at least three different viruses) into a single peptide pool for use in the immunoassay. This merging approach allows the assay to detect diverse immune responses across different individuals while maintaining a unified, single-pool format that does not require multiple separate assays, thus resolving the contradiction between versatility and complexity.
Solution Approach 2:
The multi-viral antigen pool serves multiple functions: it can assess immune competence across diverse populations, detect responses to different virus families, and provide a comprehensive immune profile. This universal approach allows a single assay system to handle various immune response patterns that would otherwise require multiple specialized assays.
2Reliability
If existing methods like Cylex Immunknow or Quantiferon Monitor are used, then the assay is commercially available and easy to perform, but they provide inconsistent results and are not suitable for determining immune responses to a wide range of individuals
Solution Approach 1:
The patent changes key parameters of the immunoassay by using a novel combination of at least three different viral antigens (from distinct virus families) instead of the single or limited antigens used in existing commercial assays. This parameter change in antigen diversity and composition improves reliability and consistency of results across different populations while maintaining ease of implementation through a standardized peptide pool format.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables a single assay system to effectively determine immune competence across a wide range of individuals, providing reliable results for identifying immunocompetent and non-immunocompetent subjects, which is beneficial for clinical assessments and disease monitoring.
Implementation Method 1
conducting a cell-mediated immunoassay (CMI) on a sample comprising immune cells... detecting in vitro an immune response to a pool of peptides
Data Source
AI summary
The invention relates to a method for determining the cell mediated immune competence of a subject. The method comprises conducting a cell-mediated immunoassay (CMI) on a sample comprising immune cells from a subject. The method further comprises detecting in vitro an immune response to a pool of peptides, wherein the pool of peptides is derived from at least three viral antigens.